17-Aag Inhibits Vemurafenib-Associated MAP Kinase Activation and Is Synergistic With Cellular Immunotherapy in a Murine Melanoma Model

PLoS ONE - United States
doi 10.1371/journal.pone.0191264
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Synergistic Effects of Vemurafenib and Fingolimod (FTY720) in Vemurafenib‑resistant Melanoma Cell Lines

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

Effects of Macrofungal Polysaccharides Combined With Vemurafenib on Melanoma and Its Associated Mechanism

International Journal of Polymer Science
PolymersPlastics
2019English

Angiostatin Inhibits Endothelial and Melanoma Cellular Invasion by Blocking Matrix-Enhanced Plasminogen Activation

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
1999English

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

Oncologist
Cancer ResearchMedicineOncology
2013English

Rheb Is in a High Activation State and Inhibits B-Raf Kinase in Mammalian Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2002English

Systematic Review and Meta-Analysis of Prevalence of Dermatological Toxicities Associated With Vemurafenib Treatment in Patients With Melanoma

Clinical and Experimental Dermatology
Dermatology
2018English

Metastatic Melanoma and Vemurafenib: Novel Approaches

Rare Tumors
OncologyHistology
2012English

Trypanosoma Cruzi: Phosphatidylinositol 3-Kinase and Protein Kinase B Activation Is Associated With Parasite Invasion

Experimental Cell Research
Cell Biology
2001English

Combination of Rapamycin, CI-1040, and 17-Aag Inhibits Metastatic Capacity of Prostate Cancer via Slug Inhibition

PLoS ONE
Multidisciplinary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy